Microbiome Research is Pushing New Horizons: Seventure Partners

4e002020-9332-4255-9010-8e2633e7b22farticleimage.jpg

13 June 2017 --- Rapidly advancing understanding of the relationship between humans and their symbiotic microbes, and how their imbalance (dysbiosis) triggers or contributes to diseases will transform opportunities for novel nutritional, diagnostic and therapeutic products, says a new report by Seventure Partners, a French venture capital firm targeting life sciences companies.

Published today at the start of the Microbiome Discovery and Development Congress in Berlin, the report, entitled The Human Microbiome: A New Protagonist in Managing Human Health, focuses on the gut microbiome, and describes recent scientific advances and the reaction of the life sciences and healthcare industry to this emerging field.

The report discusses the need to embrace dysbiosis, the holistic nature of the gut microbiome’s effects on the body and focuses on the micro-ecology – new targets and tools needed to decipher the microbiome. The report also delves into the issues around paradigm shift and opportunities in the field, highlighting those companies and the forefront of microbiome research and development.

Industry has already embraced the potential of the microbiome – from the small start-up to large corporates. In the report, Dr. Dirk Gevers, Global Head, Janssen Human Microbiome Institute, Johnson & Johnson says that “inevitably, the patient journey of the future will combine elements of microbiome diagnostics and prescription drugs, with host-specific therapy and nutrition.”

“Investing in the microbiome was considered exotic when we started six years ago. With a market predicted to be worth over half a billion US dollars by 2022, investing in microbiome based companies is now rapidly becoming mainstream, with an exponential growth of innovative companies being founded to develop products based on new biological insights,” says Isabelle de Crémoux, CEO and Managing Partner at Seventure Partners.

A total of US$744m was privately invested in microbiome companies focused on oncology, metabolic disease, infectious disease, gastrointestinal (GI) disorders and Clostridium difficile between 2011 and 2016. While over a third was invested in developing treatments for GI disorders (including Crohn’s disease and ulcerative colitis), 6% of the total was invested in the emerging oncology/microbiome interface. Metabolic diseases received a 16% split, while infectious diseases took a fifth. Investment into Clostridium difficile stood at 22%. Geographically, over US$600m was invested in North America, with the remainder invested in Europe.

According to Seventure Partners, the report features research based on an extensive literature review, supplemented by a series of interviews with leading scientists, industry executives, entrepreneurs and investors. It includes perspectives on the impact of the microbiome on the prevention, diagnosis and treatment of chronic diseases, the interface between nutrition and the pharmaceutical industry, as well as the current and future challenges that will need to be overcome, including evolving regulatory requirements. 

The findings of the report were previewed during Seventure’s workshop during Bio-Europe Spring in Barcelona.

Speaking during a webinar on the growing interest in microbiome and digestive health, Lu Ann Williams, Director of Innovation at Innova Market Insights, notes that gut health is an important facet of the trend toward personalized nutrition, creating interesting opportunities for product development in a wide range of categories.

“Consumers have an idea that there are foods that are good or better for them, and this is really the start of a personalized nutrition phase for the food industry.”

Despite strict regulations on health claims on consumer products in regions such as the EU, Williams points out that “Globally, we have seen a +25 percent growth over 2012 to 2016 for Food and Beverage launches with a digestive health claim.”

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

MenaQ7 Full Spectrum K2 closest ingredient to dietary cheese intake, study finds

20 Apr 2018 --- Based on a global state of vitamin K2 deficiency and the strong evidence showing it is a cardio-protective nutrient, researchers recommend cheese as a component of a heart-healthy diet due to its vitamin K2 content. However, for those unable to consume enough cheese daily, NattoPharma has introduced its MenaQ7 Full Spectrum K2, which aims to deliver the range of menaquinones found in foods.

Nutrition & Health News

Weekly Digest: Omega 3 fatty acids health halo widens, NP Nutra organics line gets green boost

20 Apr 2018 --- The past seven days in the Nutrition world has seen research findings suggesting that omega 3 fatty acid supplementation could protect against the potential negative outcomes of smoking during pregnancy, such a preterm birth. Regarding new product launches, Nature’s Power Nutraceuticals corp (NP Nutra) has added two new powders to their sustainable, organic, green ingredients line in honor of world Earth day; Cambridge Commodities has released a customizable range of vitamin and mineral blends, coined Blendev, and off the back of successful product launches this year, Rousselot and Peptan commit to future innovations through customer engagement days. Lastly, Lycored has released its innovative plans for engaging customers at Vitafoods: with an interactive installation which tells the story of lycopene, a carotenoid found in tomatoes.

Nutrition & Health News

Infant food allergy linked to genetics and skin exposure to food, dust and wipes

19 Apr 2018 --- Food allergy is triggered by perfect storm of genetics and skin exposure to infant wipes, dust and food, according to a new Northwestern Medicine study. Infant and childhood food allergy, whose cause has long been a mystery, has now been linked to a mix of environmental and genetic factors that must coexist to trigger the allergy. The factors contributing to food allergy include the genetics that alter skin absorbency, use of infant cleansing wipes that leave soap on the skin, skin exposure to allergens in dust and skin exposure to food from those providing infant care. Food allergy is triggered when these factors occur together.

Nutrition & Health News

Plant-based possibilities: Report details novel sugar replacements for beverages

19 Apr 2018 --- PreScouter, a Chicago based technology scouting company, details novel replacements for sugars in a new analysis, that are from natural sources, safe, technologically viable and environmentally stable, for use in beverages. The company hopes that the report answers consumer calls for sweeteners that are both natural and healthy, in light of diabetes and obesity epidemics, and that it may aid informing beverage providers on how to best respond to calls for lowering sugar levels in drinks.

Nutrition & Health News

New study sheds light on non-celiac gluten avoidance

18 Apr 2018 --- People who avoid gluten in their diets, often avoid other food types – such as dairy and eggs – and are more likely to experience frequent adverse physiological symptoms after food consumption. The research sought to uncover why the popularity of gluten-free diets has risen so much amongst those who do not have medical gluten sensitivities.

More Articles
URL : http://www.nutritioninsight.com:80/news/microbiome-research-is-pushing-new-horizons-seventure-partners.html